NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $8.77 -0.16 (-1.79%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$8.93 +0.16 (+1.77%) As of 03/14/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Immunome Stock (NASDAQ:IMNM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunome alerts:Sign Up Key Stats Today's Range$8.75▼$9.1650-Day Range$8.73▼$11.8352-Week Range$8.39▼$26.70Volume453,030 shsAverage Volume896,133 shsMarket Capitalization$699.64 millionP/E RatioN/ADividend YieldN/APrice Target$27.17Consensus RatingBuy Company OverviewImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More… Remove Ads Immunome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreIMNM MarketRank™: Immunome scored higher than 40% of companies evaluated by MarketBeat, and ranked 734th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 2 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.35% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.35% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.62 News SentimentImmunome has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Immunome this week, compared to 4 articles on an average week.MarketBeat Follows14 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,162,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNM Stock News HeadlinesWhat is Lifesci Capital's Estimate for Immunome Q1 Earnings?March 15 at 2:23 AM | americanbankingnews.comLifesci Capital Predicts Immunome FY2024 EarningsMarch 15 at 1:21 AM | americanbankingnews.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 15, 2025 | Altimetry (Ad)LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform RecommendationMarch 12 at 2:25 PM | msn.comImmunome (NASDAQ:IMNM) Earns Outperform Rating from Analysts at Lifesci CapitalMarch 12 at 3:17 AM | americanbankingnews.comImmunome initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Earns "Outperform" Rating from WedbushMarch 11, 2025 | americanbankingnews.comImmunome doses first patient in IM-1021 trialMarch 10, 2025 | markets.businessinsider.comSee More Headlines IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $10.62 at the beginning of 2025. Since then, IMNM shares have decreased by 17.4% and is now trading at $8.77. View the best growth stocks for 2025 here. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative trailing twelve-month return on equity of 48.63%. When did Immunome IPO? Immunome (IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. Who are Immunome's major shareholders? Top institutional shareholders of Immunome include T. Rowe Price Investment Management Inc. (6.89%), Redmile Group LLC (6.05%), Enavate Sciences GP LLC (4.36%) and Janus Henderson Group PLC (4.33%). Insiders that own company stock include Max Rosett, Bruce Turner, Philip Tsai, Jack Higgins and Robert Lechleider. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunome own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/15/2021Today3/14/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNM CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$27.17 High Stock Price Target$35.00 Low Stock Price Target$20.00 Potential Upside/Downside+209.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($8.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-3,014.59% Pretax Margin-3,014.59% Return on Equity-48.63% Return on Assets-41.62% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio6.17 Sales & Book Value Annual Sales$10.13 million Price / Sales69.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book3.17Miscellaneous Outstanding Shares79,777,000Free Float72,916,000Market Cap$699.64 million OptionableOptionable Beta1.93 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:IMNM) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.